A Study for Expanding Application Sites for Rotigotine Transdermal Patch

Table 1

Patients characteristics.

	N = 30 (mean ± SD)
M/F	12/18
Age (year of age)	76 ± 5.6
Hoehn-Yahr stage	3.0 ± 0.85
Disease duration (year)	14 ± 4.6
Dosage of rotigotine (mg)	13.65 ± 6.82
LED (levodopa equivalent dosage: mg)	994.83 ± 212.83
MDS-UPDRS part III (approved sites)	35 ± 11.3